Although a drawdown in the short term is a real possibility, investors should still see a 4.5% to 6% real return over the long run, says Morningstar's Matt Coffina.
Investors concerned with Express Scripts' integration of Medco are overlooking the firm's long-term potential to benefit from an increased focus on health-care cost-cutting, says Morningstar StockInvestor editor Matt Coffina.
In a fully valued market, there are worse things than buying wide-moat names at decent discounts.
StockInvestor editor Paul Larson discusses the importance of investing in companies that can compound their intrinsic values, buying on the cheap, avoiding stop-loss orders, and more.
Morningstar's Bob Johnson sees the addition of jobs in the higher-paying sectors and a stable hours-worked metric as good signs for the labor market.
The financial crisis proved that tumultuous events can and do happen, and investors need to keep a long-term perspective in a market that is incredibly short-term focused, says StockInvestor editor Paul Larson .
StockInvestor editor Paul Larson details recent changes to Morningstar's Wide Moat Focus Index, noting how the rally in wide-moat names could have them more fairly priced than lower-quality stocks.
Recent decelerating revenue growth has disappointed investors but is a temporary phenomenon, says Morningstar StockInvestor editor Matt Coffina.
Tax advantages and economic moats allow master limited partnerships to offer investors much more than just high yields, says Morningstar's Paul Larson .
Competitive advantages improved for one health-care firm, while a spin-off at another narrowed its moat, says Morningstar's Paul Larson in his discussion on recent moat-rating upgrades and downgrades.